Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 8/20 | 0.65 |
| ▸ | THRA | P10827 | 6/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRD2 | P25440 | 1/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4961785 | 0.96 | THRB (0.59) | THRBTHRACNR1CNR2EPHX1 | |
| SCHEMBL1642148 | 0.91 | THRB (0.76) | THRBTHRA | |
| SCHEMBL6663646 | 0.90 | THRB (0.58) | THRBTHRACNR1CNR2LMNA | |
| SCHEMBL6661457 | 0.88 | THRB (0.56) | THRBTHRACNR1CNR2MEN1 | |
| SCHEMBL6657934 | 0.88 | THRB (0.55) | THRBTHRACNR1CNR2MEN1 | |
| SCHEMBL1640725 | 0.88 | THRB (0.84) | THRBTHRAEPHX1EPHX2MEN1 | |
| SCHEMBL4961712 | 0.87 | THRB (0.73) | THRBTHRAEPHX1EPHX2 | |
| SCHEMBL6660463 | 0.86 | THRB (0.55) | THRBTHRA | |
| SCHEMBL4961486 | 0.86 | THRB (0.79) | THRBTHRAEPHX1EPHX2MEN1 | |
| SCHEMBL6660665 | 0.85 | THRB (0.61) | THRBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268404-B1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PROD INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2007-07-26 | — | — | US | disclosed |
| US-7202275-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | WARNER LAMBERT COMPANY LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P | 2005-09-22 | — | — | US | disclosed |
| US-6924310-B2 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | CHIANG YUAN-CHING P (US) | 2004-04-22 | — | — | US | disclosed |
| US-6664291-B2 | Aromatic amidealkyl acid or ester or amide or hydroxy derivatives are useful in the treatment of obesity, overweight condition, hyperlipidemia, glucoma, cardiac arrhythmias, thyroid disease, skin disoders and diabetes | PFIZER, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1268404-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | PFIZER INC. | 2001-12-13 | — | — | US | disclosed |
| WO-2001072692-A1 | MALONAMIC ACIDS AND DERIVATIVES THEREOF AS THYROID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173548-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRB 4/4885THRA 1/4885CNR1 835/4885 |
| US-20050209333-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRB 4/4885THRA 1/4885CNR1 835/4885 |
| US-20040077694-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, TSHR | THRB 4/4885THRA 1/4885CNR1 749/4885 |
| US-20010051657-A1 | Malonamic acids and derivatives thereof as thyroid receptor ligands | THRA, MC1R, THRB | THRB 3/4885THRA 1/4885CNR1 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.